 Onconova Therapeutics Inc NASDAQ: ONTX has announced preliminary data from Phase 12a trial of rigosertib plus Bristol-Myers Squibb Cos NYSE: BMY Opdivo nivolumab in advanced KRAS mutated non-small cell lung cancer NSCLC. The trial included patients who failed two or more lines of prior therapy, and all have failed immune checkpoint inhibitors in various combinations. 